{
    "2020-07-22": [
        [
            {
                "time": "2020-08-15",
                "original_text": "康泰生物(300601)2020年中报点评：二季度业绩恢复快速增长 在研产品逐步迎来收获期",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "二季度",
                        "业绩增长",
                        "在研产品",
                        "收获期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-07-30",
                "original_text": "125家药企半年报预告出炉，康泰生物Q2环比100倍增长，药明康德、华海药业",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "Q2",
                        "环比增长",
                        "药明康德",
                        "华海药业"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-09-05",
                "original_text": "现金流大降八成 3年股价涨近50倍的康泰生物估值贵了？",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "现金流下降",
                        "估值",
                        "股价上涨"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-09-10",
                "original_text": "康泰生物现金流大降八成 公司称形成坏账可能性较小｜公司问答 运营能力下降",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "现金流下降",
                        "坏账风险",
                        "运营能力"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-08-20",
                "original_text": "康泰生物上半年净利润持平 10亿投新型疫苗研发产业化",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "净利润持平",
                        "新型疫苗",
                        "研发投入"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-08-25",
                "original_text": "康泰生物(300601)2020年中报点评：四联苗加速恢复 23价贡献业绩弹性",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "四联苗",
                        "23价疫苗",
                        "业绩弹性"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-09-01",
                "original_text": "康泰生物：四联苗销量恢复快速增长，乙肝疫苗短期拖累业绩",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "四联苗",
                        "乙肝疫苗",
                        "业绩拖累"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2020-08-30",
                "original_text": "康泰生物二季度业绩超去年同期 12个在研项目进入注册程序",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "二季度",
                        "业绩增长",
                        "在研项目",
                        "注册程序"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-09-15",
                "original_text": "康泰生物二季度业绩 狂飙逾六成 机构抱团1370亿估值是否“高处不胜寒”？",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "二季度",
                        "业绩增长",
                        "机构抱团",
                        "估值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-09-20",
                "original_text": "刘格菘重仓股康泰生物扭转局面业绩微增 回款能力减弱现金流巨降",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "刘格菘",
                        "业绩微增",
                        "回款能力",
                        "现金流下降"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-09-25",
                "original_text": "康泰生物Q2业绩狂飙逾六成 机构对其估值现分歧",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "Q2",
                        "业绩增长",
                        "机构分歧",
                        "估值"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}